
New findings on spinal muscular atrophy
Researchers investigate the impact on the immune system.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Obara M, Shandheep A, Rahmel-Stein K, Bruhn M, Costa B, Sujariyakul P, Pavlou A, Busker L, Hook S, Tamm S, Lange B, Schröder L, Kamp J, Stanke F, Ott M, Kalinke U
Grondman I, Koeken V, Couwenbergh T, Karageorgos A, Li W, Antonakos N, Zhang B, Damoraki G, van der Heijden W, Xu C, Giamarellos-Bourboulis E, Li Y, Netea M
Krooss S, Yang T, Yuan Q, Drick N, Sgodda M, Held J, Behrendt P, Hartleben B, Koczulla R, Ma X, Liu Y, Wedemeyer H, Janciauskiene S, Di Donato N, Cantz T, Wang Z, Wu Y, Hoeper M, Xia Q, Ott M
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
The project investigates the factors that determine the species barrier mechanism of HCV and make it impossible to study the infection in animal models. The aim is to use genetic screening systems to develop in vivo models for vaccine research.
Human, potentially neutralizing antibodies against HEV have advanced the development of new detection methods for the virus in patient samples. Serological and functional analyses are used to determine markers for the course and treatment of chronic infections.
Thanks to high-throughput sequencing, genome sequences of hundreds of bacterial strains can be analyzed efficiently, revealing differences of up to 60 % in gene content, as in E. coli. With the help of machine learning, we want to better predict the functions of accessory genes and decipher their contribution to survival in specialized niches.
There are currently no events.

